| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
PMD Stock Overview
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally.
Psychemedics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.49 |
| 52 Week High | US$8.90 |
| 52 Week Low | US$6.01 |
| Beta | 0.62 |
| 1 Month Change | 3.34% |
| 3 Month Change | 0.78% |
| 1 Year Change | -5.39% |
| 3 Year Change | -10.85% |
| 5 Year Change | -66.84% |
| Change since IPO | -39.23% |
Recent News & Updates
Psychemedics GAAP EPS of -$0.06, revenue of $6.51M
Psychemedics press release (NASDAQ:PMD): Q2 GAAP EPS of -$0.06. Revenue of $6.51M (+6.9% Y/Y).
Shareholder Returns
| PMD | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -0.7% | 2.2% | 3.6% |
| 1Y | -5.4% | 14.0% | -9.6% |
Return vs Industry: PMD underperformed the US Healthcare industry which returned 14.7% over the past year.
Return vs Market: PMD exceeded the US Market which returned -10.2% over the past year.
Price Volatility
| PMD volatility | |
|---|---|
| PMD Average Weekly Movement | 4.1% |
| Healthcare Industry Average Movement | 8.7% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PMD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PMD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 139 | Ray Kubacki | https://www.psychemedics.com |
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time.
Psychemedics Fundamentals Summary
| PMD fundamental statistics | |
|---|---|
| Market Cap | US$37.41m |
| Earnings (TTM) | -US$1.18m |
| Revenue (TTM) | US$26.13m |
1.4x
P/S Ratio-30.9x
P/E RatioIs PMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMD income statement (TTM) | |
|---|---|
| Revenue | US$26.13m |
| Cost of Revenue | US$16.16m |
| Gross Profit | US$9.97m |
| Other Expenses | US$11.16m |
| Earnings | -US$1.18m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 38.17% |
| Net Profit Margin | -4.52% |
| Debt/Equity Ratio | 7.7% |
How did PMD perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield-90%
Payout RatioDoes PMD pay a reliable dividends?
See PMD dividend history and benchmarks| Psychemedics dividend dates | |
|---|---|
| Ex Dividend Date | Aug 23 2022 |
| Dividend Pay Date | Sep 09 2022 |
| Days until Ex dividend | 6 days |
| Days until Dividend pay date | 23 days |
Does PMD pay a reliable dividends?
See PMD dividend history and benchmarksValuation
Is PMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PMD?
Other financial metrics that can be useful for relative valuation.
| What is PMD's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$37.41m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 23.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does PMD's PS Ratio compare to its peers?
| PMD PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.3x | ||
CCEL Cryo-Cell International | 1.5x | n/a | US$48.3m |
VVOS Vivos Therapeutics | 1.9x | 27.6% | US$32.4m |
CTEK CynergisTek | 0.9x | 20.2% | US$15.9m |
AIH Aesthetic Medical International Holdings Group | 0.7x | n/a | US$66.3m |
PMD Psychemedics | 1.4x | n/a | US$37.4m |
Price-To-Sales vs Peers: PMD is expensive based on its Price-To-Sales Ratio (1.4x) compared to the peer average (1.3x).
Price to Earnings Ratio vs Industry
How does PMD's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: PMD is good value based on its Price-To-Sales Ratio (1.4x) compared to the US Healthcare industry average (1.5x)
Price to Sales Ratio vs Fair Ratio
What is PMD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate PMD's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of PMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PMD ($6.49) is trading above our estimate of fair value ($2.17)
Significantly Below Fair Value: PMD is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Psychemedics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
12.9%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Psychemedics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Psychemedics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
Past Performance
How has Psychemedics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-60.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PMD is currently unprofitable.
Growing Profit Margin: PMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PMD is unprofitable, and losses have increased over the past 5 years at a rate of 60.6% per year.
Accelerating Growth: Unable to compare PMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PMD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8.1%).
Return on Equity
High ROE: PMD has a negative Return on Equity (-9.89%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Psychemedics's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: PMD's short term assets ($10.9M) exceed its short term liabilities ($5.3M).
Long Term Liabilities: PMD's short term assets ($10.9M) exceed its long term liabilities ($3.2M).
Debt to Equity History and Analysis
Debt Level: PMD has more cash than its total debt.
Reducing Debt: PMD's debt to equity ratio has reduced from 9.8% to 7.7% over the past 5 years.
Debt Coverage: PMD's debt is well covered by operating cash flow (91.8%).
Interest Coverage: Insufficient data to determine if PMD's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Dividend
What is Psychemedics's current dividend yield, its reliability and sustainability?
Dividend Score
2/6Dividend Score 2/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
4.31%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: PMD's dividend (4.31%) is higher than the bottom 25% of dividend payers in the US market (1.47%).
High Dividend: PMD's dividend (4.31%) is in the top 25% of dividend payers in the US market (3.95%)
Stability and Growth of Payments
Stable Dividend: PMD's dividend payments have been volatile in the past 10 years.
Growing Dividend: PMD's dividend payments have fallen over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: PMD is paying a dividend but the company is unprofitable.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (235.5%), PMD's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
23.6yrs
Average management tenure
CEO
Ray Kubacki (77 yo)
31.58yrs
Tenure
US$623,852
Compensation
Mr. Raymond C. Kubacki, also known as Ray, has been the President and Chief Executive Officer at Psychemedics Corporation since July 1991. Prior to joining Psychemedics Corporation, Mr. Kubacki served as V...
CEO Compensation Analysis
Compensation vs Market: Ray's total compensation ($USD623.85K) is about average for companies of similar size in the US market ($USD759.98K).
Compensation vs Earnings: Ray's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: PMD's management team is seasoned and experienced (23.6 years average tenure).
Board Members
Experienced Board: PMD's board of directors are seasoned and experienced ( 23.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Psychemedics Corporation's employee growth, exchange listings and data sources
Key Information
- Name: Psychemedics Corporation
- Ticker: PMD
- Exchange: NasdaqCM
- Founded: 1986
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$37.414m
- Shares outstanding: 5.63m
- Website: https://www.psychemedics.com
Number of Employees
Location
- Psychemedics Corporation
- 289 Great Road
- Suite 200
- Acton
- Massachusetts
- 1720
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/15 00:00 |
| End of Day Share Price | 2022/08/15 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.